Merck Joins Obesity Pill Race With $2B Hansoh Deal

By /

The Hansoh deal will let Merck compete in the crowded oral GLP-1 space alongside fellow pharma giants Eli Lilly, Novo Nordisk and Roche.

Scroll to Top